Clinical Trial Update: Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the efficacy and safety of HDM1005 for obesity/overweight in Chinese patients without diabetes is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• HDM1005

Snippet

Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Conditions: Obesity & Overweight | Phase 3 | Status: RECRUITING